ZBH trading volume has lost -39533 shares compared to readings over the past three months as it recently exchanged 1310467 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 1350000 shares, and this is 0.97 times the normal volume. A look at its technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 61.5 point.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) climbed by 9.76% over the past three months which led to its overall six-month decrease to stand at -0.27%. The equity price rose 1.28% this week, a trend that has led to both investors and traders taking note of the stock. A look at its monthly performance shows that its shares have recorded a -0.81% fall over the past 30 days. Over the past 12 months the stock has embarked on a rally that has seen it rise 4.26% and is now up by 18.53% since start of this year.
The shares of Zimmer Biomet Holdings, Inc. dropped by -8.63% or -$11.61 from its last recorded high of $134.55 which it attained on September 21 to close at $122.94 per share. Over the past 52 weeks, the shares of Zimmer Biomet Holdings, Inc. has been trading as low as $96.99 before witnessing a massive surge by 26.76% or $25.95. This price movement has led to the ZBH stock receiving more attention and has become one to watch out for. It dipped by -0.15% on Thursday and this got the market worried. The stock’s beta now stands at 1.25 and when compared to its 200-day moving average and its 50-day moving average, ZBH price stands 4.88% above and 7.37% above respectively. Its average daily volatility for this week is 1.42% which is less than the 1.42% recorded over the past month.
Experts from research firms are bullish about the near-term performance of Zimmer Biomet Holdings, Inc. (ZBH) with most of them predicting a $131.75 price target on a short-term (12 months) basis. The average price target by the analysts will see a 7.17% rise in the stock and would lead to ZBH’s market cap to surge to $26.88B. The stock has been rated an average 2.3, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 32 analysts that track Zimmer Biomet Holdings, Inc. (NYSE:ZBH) and find out that 12 of them rated it as a Hold. 17 of the 20 analysts rated it as a Buy or a Strong Buy while 3 advised investors to desist from buying the stock or sell it if they already possess it.
The price of Brunswick Corporation (NYSE:BC) currently stands at $52.96 after it went down by $-0.06 or -0.11% and has found a strong support at $52.59 a share. If the BC price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $52.23 mark would also be bad for the stock as it means that the stock would plunge by 1.38% from its current position. However, if the stock price is able to trade above the resistance point around $53.39, then it could likely surge higher to try and break the upward resistance which stands at $53.83 a share. Its average daily volatility over the past one month stands at 2.2%. The stock has plunged by 0.57% from its 52-weeks high of $52.66 which it reached on Sep. 19, 2018. In general, it is 20.85% above its 52-weeks lowest point which stands at $41.92 and this setback was observed on Dec. 24, 2018.
Analysts have predicted a price target for Brunswick Corporation (BC) for 1 year and it stands at an average $67.82/share. This means that it would likely increase by 28.06% from its current position. The current price of the stock has been moving between $52.66 and $53.46. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $52. On the other hand, one analyst is super bullish about the price, setting a target as high as $84.
The BC stock Stochastic Oscillator (%D) is at 51.2%, which means that it is currently neutral. The shares P/S ratio stands at 0.9 which compares to the 2.79 recorded by the industry or the 2 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 9.35, which is lower than the 18.09 multiple of 12-month price-earnings (P/E). The company’s earnings have gone down, with a quarterly decrease rate of -18.4% over the past five years.
Analysts view Brunswick Corporation (NYSE:BC) as a Buy, with 1.8 consensus rating. Reuters surveyed 18 analysts that follow BC and found that 2 of those analysts rated the stock as a Hold. The remaining 16 were divided, with 16 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying Brunswick Corporation (BC) shares or sell it if they already own it.